4.8 Article

Complete Revascularization with Multivessel PCI for Myocardial Infarction

期刊

NEW ENGLAND JOURNAL OF MEDICINE
卷 381, 期 15, 页码 1411-1421

出版社

MASSACHUSETTS MEDICAL SOC
DOI: 10.1056/NEJMoa1907775

关键词

-

资金

  1. Canadian Institutes of Health Research
  2. AstraZeneca
  3. Boston Scientific
  4. Population Health Research Institute
  5. PlaqueTec
  6. Thromboserin
  7. Glycardial Diagnostics
  8. Abbott Laboratories
  9. Bayer
  10. CSL Behring
  11. Daiichi-Sankyo
  12. Medtronic
  13. Novartis
  14. OrbusNeich
  15. Bristol-Myers Squibb
  16. Bayer-Janssen
  17. Merck
  18. Sanofi
  19. Amarin
  20. Servier
  21. Boehringer Ingelheim

向作者/读者索取更多资源

Background In patients with ST-segment elevation myocardial infarction (STEMI), percutaneous coronary intervention (PCI) of the culprit lesion reduces the risk of cardiovascular death or myocardial infarction. Whether PCI of nonculprit lesions further reduces the risk of such events is unclear. Methods We randomly assigned patients with STEMI and multivessel coronary artery disease who had undergone successful culprit-lesion PCI to a strategy of either complete revascularization with PCI of angiographically significant nonculprit lesions or no further revascularization. Randomization was stratified according to the intended timing of nonculprit-lesion PCI (either during or after the index hospitalization). The first coprimary outcome was the composite of cardiovascular death or myocardial infarction; the second coprimary outcome was the composite of cardiovascular death, myocardial infarction, or ischemia-driven revascularization. Results At a median follow-up of 3 years, the first coprimary outcome had occurred in 158 of the 2016 patients (7.8%) in the complete-revascularization group as compared with 213 of the 2025 patients (10.5%) in the culprit-lesion-only PCI group (hazard ratio, 0.74; 95% confidence interval [CI], 0.60 to 0.91; P=0.004). The second coprimary outcome had occurred in 179 patients (8.9%) in the complete-revascularization group as compared with 339 patients (16.7%) in the culprit-lesion-only PCI group (hazard ratio, 0.51; 95% CI, 0.43 to 0.61; P<0.001). For both coprimary outcomes, the benefit of complete revascularization was consistently observed regardless of the intended timing of nonculprit-lesion PCI (P=0.62 and P=0.27 for interaction for the first and second coprimary outcomes, respectively). Conclusions Among patients with STEMI and multivessel coronary artery disease, complete revascularization was superior to culprit-lesion-only PCI in reducing the risk of cardiovascular death or myocardial infarction, as well as the risk of cardiovascular death, myocardial infarction, or ischemia-driven revascularization. (Funded by the Canadian Institutes of Health Research and others; COMPLETE ClinicalTrials.gov number, NCT01740479.). Patients with ST-segment elevation MI and multivessel coronary disease who had undergone successful culprit-lesion PCI were assigned to a strategy of either PCI of all other suitable stenoses or no further revascularization. At 3 years, the risk of cardiovascular death or new MI was lower with complete revascularization.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据